BioSyent Announces Closing of the Acquisition of Oral Science Inc.
MWN-AI** Summary
BioSyent Inc. has announced the successful closure of its acquisition of Oral Science Inc., a Canadian distributor specializing in dental hygiene and oral health products. The deal was formalized under a Share Purchase Agreement dated February 8, 2026, for a total purchase price of $25.5 million. This price includes a cash payment of $22.5 million, which entails a small portion being compensated with 12,666 Restricted Share Units (RSUs) for specific Oral Science employees, to vest on their second anniversary. Additionally, BioSyent issued 234,192 common shares valued at $3 million, divided into shares subject to a two-year escrow and lock-up.
The acquisition was financed primarily through BioSyent's available cash, alongside a $6 million term loan and a $2 million draw from a revolving credit line with RBC Royal Bank. The sellers of Oral Science will also receive contingent payments based on the company's performance over the coming years and potential royalty payments that could total up to $6 million.
Founded in 2003, Oral Science has established itself as an innovator in the dental sector, focusing on integrated solutions that enhance clinical outcomes for conditions such as periodontal diseases and dry mouth. BioSyent, listed on the TSX Venture Exchange, aims to grow in the specialty healthcare market by acquiring and distributing effective healthcare products.
This acquisition not only strengthens BioSyent’s footprint in the dental product market but is also designed to benefit healthcare providers by enhancing their product offerings. The deal is expected to be finalized pending approval from the TSXV. For more details, interested parties can refer to BioSyent’s previous announcements or contact company representatives directly.
MWN-AI** Analysis
The recent acquisition of Oral Science Inc. by BioSyent Inc. represents a strategic move that could enhance BioSyent's market position in the healthcare sector, particularly within the dental hygiene and oral health markets. With a purchase price of $25.5 million, comprising both cash and stock considerations, the acquisition not only expands BioSyent's product offerings but also integrates Oral Science’s innovative approaches and established customer base.
The deal's structure, involving significant cash outlays funded by BioSyent’s own liquidity and a short-term loan, indicates financial prudence. However, the immediate cash component at $22.5 million may pose a strain on cash flows, which investors should monitor closely post-transaction. The fact that a substantial portion of the consideration is in stock, with the Shares subject to escrows and lock-ups, aligns the interests of Oral Science’s original stakeholders with BioSyent's long-term growth. This may soothe investor concerns about dilution, provided the acquisition leads to increased revenues.
Market analysis should closely track the performance of Oral Science following the acquisition. The contingency earn-out payments based on future performance (potentially up to $6 million) highlight the anticipated growth of both companies when synergized. Given BioSyent's historical focus on innovative and proven pharmaceutical products, the integration of Oral Science’s expertise in dental solutions could yield significant returns, especially considering increasing demand for specialized oral health products.
Investors should remain optimistic, factoring in BioSyent's solid growth trajectory and existing profitability. However, potential risks, such as the need for effective integration and market acceptance of Oral Science’s products, must also be under consideration. Regular updates and performance reviews will be critical in informing ongoing investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MISSISSAUGA, Ontario, March 02, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) is pleased to announce that it has successfully closed the previously-announced acquisition of Oral Science Inc. (“Oral Science”), a privately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard, Quebec.
Pursuant to the terms of a Share Purchase Agreement (“SPA”) dated February 8, 2026, BioSyent, through its wholly-owned subsidiary, completed the acquisition of Oral Science from the shareholders of Oral Science (the “Sellers”) in an arm’s length transaction. The aggregate purchase price was $25.5 million, satisfied by: (i) a cash payment of $22.5 million to the Sellers of which $0.2 million will be satisfied with the grant of 12,666 Restricted Share Units (“RSUs”) to certain Oral Science employees pursuant to BioSyent’s RSU Plan which will fully vest on the second anniversary of the grant date; and (ii) the issue of 234,192 BioSyent common shares (the “Consideration Shares”) to the Sellers at a deemed issue price of $12.81 per share ($3.0 million in aggregate). 167,635 of the Consideration Shares are subject to a two-year escrow and 66,557 are subject to a two-year lock-up, with 25% of the locked-up shares to be released every six months. BioSyent paid to the Sellers additional cash consideration of $2.0 million on closing, representing the excess working capital of Oral Science above the $6.3 million working capital requirement pursuant to the SPA. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of $6.0 million. No finder’s fees were applicable in respect of this transaction. The cash component of the purchase consideration was funded with $16.3 million of BioSyent’s liquid cash on hand along with a $6.0 million 1-Year Senior Secured Demand Term Loan from RBC Royal Bank and a $2.0 million draw on a RBC Royal Bank Senior Secured Demand Revolving Credit Line Facility.
This transaction qualifies as an "Expedited Acquisition" under TSXV Policy 5.3: Acquisitions and Dispositions of Non-Cash Assets and remains subject to final approval by the TSXV. For more information on this transaction, please refer to BioSyent’s news release dated February 9, 2026.
BioSyent further announces that its Board of Directors has approved a grant of 8,682 RSUs to certain employees pursuant to BioSyent’s Restricted Share Unit Plan. These RSUs will fully vest on the third anniversary of the grant date.
ABOUT ORAL SCIENCE
Founded in Canada in 2003, Oral Science is a leading and innovative Canadian dental company that partners with progressive dental practices to improve clinical outcomes in periodontal disease, high-risk caries, dry mouth, and oral lesions. Supported by advanced healthcare technologies, Oral Science’s integrated approach is built on four key pillars: diagnosis and monitoring, in-office treatments, home-care solutions, and clinical team and patient education.
ABOUT BIOSYENT
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Canadian pharma, international pharma, and oral health business units.
As of the date of this press release, the Company has 11,497,447 common shares outstanding.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
FAQ**
How does the acquisition of Oral Science align with BioSyent Inc. (BIOYF)'s growth strategy and market positioning in the specialty healthcare sector?
What are the expected synergies from the BioSyent Inc. (BIOYF) acquisition of Oral Science, particularly regarding product offerings and market reach?
Can you provide insights on the financial performance metrics BioSyent Inc. (BIOYF) aims to achieve with the contingent cash earn-out from Oral Science by 2027?
How might the integration of Oral Science enhance BioSyent Inc. (BIOYF)'s capabilities in dental and oral health products, and what risks could impact this transition?
**MWN-AI FAQ is based on asking OpenAI questions about Biosyent Inc (OTC: BIOYF).
NASDAQ: BIOYF
BIOYF Trading
-0.61% G/L:
$11.45 Last:
1,316 Volume:
$11.99 Open:
